Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPR3 | P17342 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945249 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7CTSSCTSKCTSL | |
| SCHEMBL19945248 | 0.88 | ITGA4 (0.61) | ITGA4ITGB7CTSSCTSKCTSL | |
| SCHEMBL10660301 | 0.88 | CTSS (0.49) | ITGA4ITGB7CTSSCTSK | |
| SCHEMBL8150297 | 0.86 | CTSK (0.51) | ITGA4ITGB7CTSSCTSKNPR3 | |
| SCHEMBL10957814 | 0.86 | ITGA4 (0.54) | ITGA4ITGB7CTSSCTSKCTSL | |
| SCHEMBL7445836 | 0.86 | P2RX7 (0.39) | ITGA4ITGB7CTSSCTSKCTSL | |
| SCHEMBL8707158 | 0.85 | CTSS (0.61) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL22060196 | 0.81 | CTSS (0.62) | ITGA4ITGB7CTSSCTSKCTSL | |
| SCHEMBL11387995 | 0.80 | SLC7A5 (0.51) | ITGA4ITGB7CTSSCTSKCTSL | |
| SCHEMBL31293782 | 0.80 | MMP1 (0.58) | ITGA4ITGB7CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036660-A1 | Method of producing optically active N-methylamino acids | KANEKA CORPORATION (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1130107-A1 | Method of producing optically active N-methylamino acids | KANEKA CORPORATION (JP) | 2001-09-05 | — | — | EP | disclosed |
| EP-0390181-B1 | Perylenequinone (UCN-1028D) derivatives | KYOWA HAKKO KOGYO KK (JP) | 1995-05-10 | — | — | EP | disclosed |
| EP-0635479-A1 | Perylene quinones (UCN-1028 D) derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5140044-A | Antitumor and -carcinogenic agents; protein kinase C inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-08-18 | — | — | US | disclosed |
| EP-0136720-B1 | ENKEPHALIN ANALOGS | G.D. Searle & Co. (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4722922-A | RENIN INHIBITION | G. D. SEARLE & CO. (US) | 1988-02-02 | — | — | US | disclosed |
| US-4603121-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1986-07-29 | — | — | US | disclosed |
| EP-0136720-A2 | Enkephalin analogs | G.D. Searle & Co. (US) | 1985-04-10 | — | — | EP | disclosed |
| US-4510085-A | Antihypertensive tetrapeptide amides | G.D. SEARLE & CO. (US) | 1985-04-09 | — | — | US | disclosed |
| US-4495178-A | Enkephalin analogs | G. D. SEARLE & CO. (US) | 1985-01-22 | — | — | US | disclosed |
| US-4320051-A | Analgesic tripeptide amides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036660-A1 | Method of producing optically active N-methylamino acids | AMD1, KMO, AADAT | ITGA4 3468/4885ITGB7 2343/4885CTSS 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.